CBD LIFE SCIENCES INC - CBDL STOCK NEWS

CBD Life Sciences Inc. (OTC PINK:CBDL) has announced its application to list on Amazon Marketplace, following its successful launch on Walmart Marketplace. This strategic expansion aims to increase the company's e-commerce footprint by offering its top-selling CBD Pain Relief Cream Roll-On and CBD Pet Treats to Amazon's global customer base. The move is part of CBDL's multi-channel retail strategy and is expected to create new revenue streams.

Key points:

• CBDL reported a 1405.46% revenue increase since February 2024
• Amazon has over 300 million active users
• The CBD market is projected to surpass $20 billion by 2025
• CBDL is pursuing partnerships with other e-commerce giants and retail chains

CEO Lisa Nelson emphasized that this expansion is a pivotal moment for CBDL, positioning the company to dominate new market segments and accelerate revenue growth.

CBD Life Sciences Inc. (OTC PINK:CBDL) has announced a record revenue increase of 1405.46% since February 2024, highlighting the company's successful strategic initiatives and growing market demand for its premium CBD products. This growth is attributed to several factors, including:

1. The launch of Mellow Mornings nano CBD Coffee Creamer
2. Introduction of CBDL's products into the Walmart Marketplace
3. Strategic agreements, such as an MOU with a cannabis dispensary

The company has been pioneering the use of nanotechnology to enhance the bioavailability and effectiveness of its CBD products. CBD Life Sciences Inc. is actively pursuing additional market opportunities and collaborations with high-profile athletes, brands, and influencers to further elevate its brand presence.

CBD Life Sciences, Inc. (OTC PINK:CBDL) has announced the launch of its flagship product line on Walmart Marketplace, marking a significant expansion in its retail strategy. This move is expected to drive substantial revenue growth and expand market reach to millions of potential customers. Key highlights include:

1. Market Expansion: Access to Walmart's platform with over 120 million monthly visitors.
2. Revenue Growth: Projected 35% increase in annual sales due to this new distribution channel.
3. Product Line: Initial offerings include Nano CBD Coffee Creamer, Mellow Mornings, and CBD Pain Cream.
4. Investor Impact: Aim to increase gross margins by 10% while driving stronger returns for investors.

The company expects this partnership to enhance its competitive edge in the CBD sector, projected to reach $47.22 billion by 2028. CEO Lisa Nelson stated that this launch represents a monumental step forward in their growth strategy.

CBD Life Sciences, Inc. (CBDL) is set to launch a groundbreaking nutritional supplement powder infused with mushroom extracts, projected to increase company revenue by 20% in the first year. The supplement contains a proprietary blend of reishi mushroom, lion's mane mushroom, and ashwagandha root extracts, offering stress reduction, brain health support, and immune system enhancement.

Key benefits include:

• Reishi extract: Immune-boosting and potential tumor growth inhibition
• Lion's mane extract: Cognitive function enhancement and nerve regeneration
• Ashwagandha root: Stress reduction and anti-inflammatory effects

The global supplement market is expected to reach $18 billion by 2028, positioning CBDL to capture a substantial market share with this innovative product launch.

CBD Life Sciences, Inc. (OTC PINK:CBDL) has launched Mellow Mornings, a nano CBD Coffee Creamer, targeting the rapidly growing CBD coffee market. Available in Pumpkin Spice Cheesecake, Pumpkin, Vanilla, and Classic flavors, each bottle contains 1000mg of CBD. The company projects this product could add up to $2 million in annual revenue within its first year. Utilizing nanotechnology, Mellow Mornings offers superior bioavailability, making it up to 10 times more effective than traditional formulations. The CBD-infused beverage market is expected to reach $2.6 billion by 2025. Local coffee shops are already adopting Mellow Mornings for specialty CBD Lattes, indicating strong market potential.

CBD Life Sciences, Inc. (OTC PINK:CBDL) has signed a Memorandum of Understanding (MOU) to acquire a 45% ownership interest in a state-licensed Cannabis Dispensary in New York. The targeted acquisition has an estimated business value of $10 million with projected 2024 gross revenues of up to $4.5 million. The dispensary, expected to be located on Long Island, is positioned to become a key revenue generator for CBDL.

This strategic move aligns with CBDL's commitment to growth and expanding its footprint in the Northeast region. The company will be entitled to a share of the monthly profits from the dispensary's operations, subject to necessary approvals and finalization of a formal agreement. CEO Lisa Nelson expressed confidence that this endeavor will drive considerable revenue growth and reinforce CBDL's leadership in the industry.

CBD Life Sciences (OTC PINK:CBDL) is in advanced discussions to acquire a strategic minority interest in two state-licensed cannabis dispensaries in Upstate New York and Long Island. The targeted acquisitions have an estimated business value of $14 million. The Upstate New York dispensary is projected to open by November 1, 2024, with the Long Island location following in early 2025.

This strategic move aims to capture a share of New York's legal cannabis market, expected to exceed $4.2 billion by 2027. The company anticipates a 20% increase in annual revenue by the end of the first year of operations and a 15% increase in EBITDA following the dispensary openings. This expansion aligns with CBDL's growth strategy, focusing on key markets, revenue growth, and enhanced profitability.

The CBD Vault, a subsidiary of CBD Life Sciences Inc. (CBDL), is exploring distribution and joint venture opportunities in China following new CBD regulations effective September 1st. The USDA memo indicates that CBD is now integrated into China's 'precursor chemicals management system', allowing for nationwide production and marketing with proper applications. This expands beyond previous limitations to Yunnan and Heilongjiang provinces.

Lisa Nelson, President & CEO of CBDL, sees this as an opportune time to strike deals in China's CBD sector. The company is actively working with wholesalers, distributors, retailers, and merchant banks to locate new business opportunities. The CBD Vault offers a full line of cannabidiol-based and organic products, including Delta 8 & 10 Gummy's, tinctures, pain creams, and pet products, available on their website www.thecbdvault.com.

CBD Life Sciences Inc. (OTC PINK:CBDL) and its subsidiary, The CBD Vault Inc., have signed a partnership agreement with the Vienna Vikings, a premier football team in the European League of Football. The Vikings, currently 11-0 with an average attendance of 20,000+ per game, will use CBD Vault's pain relief and roll-on hemp cream for player recovery. This partnership offers significant global brand exposure for CBD Vault.

Key figures from the Vikings, including quarterback Ben Homes and director Lenard Oberladstatter, have praised the effectiveness of CBD Vault's products. Lisa Nelson, CEO of CBDL, emphasized that this partnership is a pivotal moment for expanding exposure and revenue globally, marking the beginning of a series of groundbreaking collaborations aimed at market dominance.